TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of major depressive disorder~* right handed~* adult aged 18-55~* currently depressed~Exclusion Criteria:~* clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder~* met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for alcohol and/or substance abuse or substance dependence (other than nicotine) within 12 months prior to screening~* endorse suicidal intent or have made a suicide attempt within the preceding three months~* history of traumatic brain injury~* inability to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)~* current pregnancy or breast feeding~* a primary language other than English~* received psychotropic drugs for at least 3 weeks (8 weeks for fluoxetine) prior to scanning (Effective medications will not be discontinued for the purposes of the study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- real-time fMRI neurofeedback: Amygdala (Type: EXPERIMENTAL): Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
- real-time fMRI neurofeedback: HIPS (Type: ACTIVE_COMPARATOR): HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Incompetence of SFJ~* Patients who are candidates for ETA \[laser or radiofrequency ablation (RFA)\]~* Symptomatic varicose veins~* Visible varicose veins~* Ability to comprehend and sign an informed consent and complete study questionnaires in English~Exclusion Criteria:~* Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP Classification of Venous Disorders)~* Patients who have active ulceration on the leg to be treated (Clinical Finding C6, as assessed by CEAP Classification of Venous Disorders)~* Leg obesity impairing the ability to access the vein to be treated and/or to apply post-procedure compression bandaging and stockings~* Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion~* Deep venous reflux unless clinically insignificant in comparison to superficial reflux~* Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings~* Reduced mobility~* History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of prior DVT on duplex ultrasound~* Major surgery, prolonged hospitalization or pregnancy within 3 months of screening~* Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)~* Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions~* Current alcohol or drug abuse~* Pregnant or lactating women~* Women of childbearing potential not using effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Endovenous ablation+polidocanol injectable microfoam 0.125% (Type: EXPERIMENTAL): Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
- Endovenous ablation+polidocanol injectable micrfoam, 1.0% (Type: EXPERIMENTAL): Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
- endovenous ablation+vehicle (placebo) (Type: ACTIVE_COMPARATOR): endovenous ablation followed by injection of vehicle (placebo) to target vein

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, ≥ 18 years of age;~* moderate to severe active rheumatoid arthritis (Disease Activity Score (DAS28) \> 4.4);~* inadequate response to methotrexate;~* on a stable dose of ≥ 15mg/week methotrexate for at least 6 weeks.~Exclusion Criteria:~* prior treatment with a biologic;~* Rheumatoid arthritis (RA) functional class IV;~* known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections;~* evidence of active malignant disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab + Methotrexate (Type: EXPERIMENTAL): Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
- Tocilizumab + Placebo (Type: PLACEBO_COMPARATOR): Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* locally advanced head and neck squamous cell carcinoma~* oral cavity, oropharynx, hypopharynx, larynx~* measurable lesion~* unresectable~* age 18 or more~* ECOG 0 or 1~Exclusion Criteria:~* distant metastasis~* pregnancy~* prior chemotherapy or radiation therapy~* 2ndary malignancy~* other unfit medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- genexolPM + cisplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has a body mass index (BMI) of 18.0 - 40.0 kg/m\^2~* Meets criteria for the diagnosis of schizophrenia~* Resides in a stable living situation when not hospitalized~* Is willing and able to provide government-issued identification~* Additional criteria may apply~Exclusion Criteria:~* Has had a psychiatric hospitalization for more than 30 days during the 90 days before screening~* Subject initiated first antipsychotic treatment within the past 12 months, or \<1 year has elapsed since the initial onset of active-phase of schizophrenia symptoms~* Subject poses a current suicide risk~* Subject has a history of treatment resistance~* Subject has a history of poor or inadequate response to treatment with olanzapine~* Subject requires or has had electroconvulsive therapy (ECT) treatment in the 2-month period prior to screening~* Subject has a diagnosis of moderate or severe alcohol or drug use disorder~* Subject has a positive urine drug screen for opioids, amphetamine/methamphetamine, phencyclidine, or cocaine at screening~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 3831 (Type: EXPERIMENTAL): Administered as a coated bilayer tablet
- Olanzapine (Type: ACTIVE_COMPARATOR): Administered as a coated bilayer tablet
- Placebo (Type: PLACEBO_COMPARATOR): Administered as a coated bilayer tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TNF Alpha in Refractory Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic asthma Methacholine PC20\<8mg/ml~Exclusion Criteria:~* History of poor treatment concordance History of tuberculosis Radiographic evidence of previous tuberculosis Recent tuberculosis contact Respiratory tract infection within 3 months Current Smoker or Ex-smoker with more than 5 pack years Symptomatic co-morbid condition Contra-indication to etanercept Pregancy Breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wellness Self-Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a diagnosis of schizophrenia/ schizoaffective disorder~* bipolar disorder~* major depression with psychotic features~* post traumatic stress disorder~* or psychosis not otherwise specified (NOS)~* age between 18 and 80~* chart documented presence of at least one of the following chronic medical conditions:~  * a respiratory condition (e.g. asthma, COPD)~ * diabetes~ * arthritis~ * cardiovascular condition (e.g. congestive heart failure, hypertension, etc.)~* receiving mental health services at a designated study site~* willing and able to provide consent to participate~* deemed clinically stable enough to participate in the study by a treatment provider~Exclusion Criteria:~* Severe or profound mental retardation~* Because participants must be able to attend the intervention if assigned to either condition, we will also require potential participants to verify their availability during screening~* Participation in current ongoing study 'Reducing Internalized Stigma in People with Serious Mental Illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Living Well (Type: EXPERIMENTAL): This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. After completing the 12 weekly groups, participants will return to complete once monthly booster group sessions for the next three months.
- Medical Illness Education & Support Group (Type: ACTIVE_COMPARATOR): We selected a comparison condition that would provide parallel focus (i.e. medical illness) but not include use of the core ingredients undergirding the Living Well intervention including behavioral action planning, problem solving, in-session and between session practice using specific disease self-management techniques and involvement of peer co-facilitators to enhance modeling and improve self-efficacy and activation. As with Living Well, the content of the intervention will have broad applicability across diverse chronic disease conditions. The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: T Cell Vaccination in Patients With Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically definite MS (according to Poser's criteria) of the relapsing-progressive type (RPMS).~2. Age: 18-60.~3. EDSS: 3.0 to 7.0.~4. Disease duration: \> 1 year.~5. Evidence of disease progression of 1 degree in the EDSS scale, or at least two severe relapses (requiring hospitalization and treatment) during the year prior to inclusion.~6. MRI of the brain with at least 5 lesions in the white matter (T2 imaging).~7. Failure to benefit from other existing treatments according to the guidelines of the Israeli Ministry of Health.~Exclusion Criteria:~1. Patients with other systemic active disease.~2. Patients who had been treated with immunosuppressive drugs during the 3-6 months depending on the cytotoxicity of the medication used prior to the inclusion.~3. Patients who previously received cellular immunotherapy or who are participating in other experimental protocols.~4. Pregnancy; Pregnant women or women who do not use efficacious contraception (oral contraception, or intra-uterine device).~5. Patients with an additional autoimmune condition unrelated to MS or significant allergy.~6. Patients who cannot fully understand the treatment protocol or are unable to sign the informed consent, or in whom the clinician believes that a follow-up period of at least 12 months will not be possible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- TCV (Type: ACTIVE_COMPARATOR): multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
- Placebo (Type: SHAM_COMPARATOR): saline injections subcutaneously at the same 4 time points with active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Erectile Dysfunction I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male, at least 19 years of age~* Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity~* History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration~* Partner is not pregnant or lactating~Exclusion Criteria:~* History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months~* Cardiac arrhythmias requiring antiarrhythmic treatment~* Symptomatic congestive heart failure~* Taking nitrate medication in any form~* Uncontrolled diabetes (HbA1c ≥ 13%)~* Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®~* Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Udenafil 50 mg (Type: EXPERIMENTAL): None
- Udenafil 100 mg (Type: EXPERIMENTAL): None
- Udenafil 150 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Nonintubated Uniport Thoracoscopic Surgery Using Thoracic Paravertebral Nerve Block Versus Intercostal Nerve Block for Peripheral Solitary Pulmonary Nodule Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* the undetermined peripheral solitary pulmonary nodule or tuberculoma was enrolled~* the well cardiopulmonary function~* age between 18 and 65 years old~* less airway secretion~* body mass index less than 25~* I to II grade of the American Society of Anesthesiologists~* no metabolic diseases~Exclusion Criteria:~* refusal or inability to comply with the informed consent~* the nodule of the nature of the non small cell lung caner is excluded~* hypovolemia, blood disorders or abnormal clotting mechanism~* the abnormal cardiopulmonary function(the American Society of Anesthesiologists greater than 3)~* lower airway infection,more than airway secretion~* abnormal anatomy of the spine,the history of thoracic back surgery~* impaired lung function(forced expiratory volume in second 1 less than predicted), or asthma uncontrolled on medications~* constrained cardiac output such as hypertrophic cardiomyopathy, mitral stenosis or complete atrioventricular block~* extensive pleural adhesion~* overweight (body mass index no less than 25)~* difficulty airway~* chronic pain score more than 5 before the surgery~* the history of bilateral thoracotomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- paravertebral nerve block group (Type: EXPERIMENTAL): non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
- intercostals nerve block group (Type: ACTIVE_COMPARATOR): non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* HbA1C: At least 8%~* Patients that were never treated with insulin before~* Current therapy with metformin and a sulfonylurea.~Exclusion Criteria:~* History of recurrent, severe hypoglycemia~* Hepatic insufficiency: ALT, AST or alkaline phosphatase \> 2.5 times upper limits of laboratory's normal~* Renal insufficiency: serum creatinine \> 1.3 mg/dL (males) or \> 1.2 mg/dL (females)~* Severe gastrointestinal disease, including gastroparesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete